Medicare EpiPen spending outpaces prescription growth -Kaiser report

NEW YORK, Sept 20 (Reuters) - U.S. government spending on

Mylan Inc's EpiPen in the Medicare program for seniors

and the disabled rose 1,151 percent from 2007 through 2014,

while the number of EpiPen users grew 164 percent, the Kaiser

Family Foundation said on Tuesday in an analysis.

Read more